Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiogenesis
Research from Duke University in the area of angiogenesis published
October 14th, 2008
According to recent research from the United States, "Glioblastoma multiforme (GBM), a highly invasive and vascular cancer, responds poorly to conventional cytotoxic therapy. Integrins, widely expressed in GBM and tumor vasculature, mediate cell survival, migration and angiogenesis." "Cilengitide is a potent (alpha v beta 3 and alpha v beta 5 integrin inhibitor. To summarize the preclinical and clinical experience with cilengitide for GBM. Preclinical studies and clinical trials evaluating cilengitide for GBM were reviewed. Cilengitide is active and synergizes with external beam radiotherapy in preclinical GBM models. In clinical trials for recurrent GBM, single-agent...
Source: Cancer Weekly (2008-10-14)
|
